Cargando…

Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study

BACKGROUND: Pulmonary multi-drug-resistant tuberculosis (MDR TB) alters lung architecture and involves lengthy treatment duration, high pill burden, drug adverse effects, travel restrictions, and stigma. Literature about pulmonary function and health-related quality of life (QoL) of patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuwagira, Edwin, Stadelman, Anna, Baluku, Joseph Baruch, Rhein, Joshua, Byakika-Kibwika, Pauline, Mayanja, Harriet, Kunisaki, Ken M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236316/
https://www.ncbi.nlm.nih.gov/pubmed/32476983
http://dx.doi.org/10.1186/s41182-020-00221-y
_version_ 1783536132060872704
author Nuwagira, Edwin
Stadelman, Anna
Baluku, Joseph Baruch
Rhein, Joshua
Byakika-Kibwika, Pauline
Mayanja, Harriet
Kunisaki, Ken M.
author_facet Nuwagira, Edwin
Stadelman, Anna
Baluku, Joseph Baruch
Rhein, Joshua
Byakika-Kibwika, Pauline
Mayanja, Harriet
Kunisaki, Ken M.
author_sort Nuwagira, Edwin
collection PubMed
description BACKGROUND: Pulmonary multi-drug-resistant tuberculosis (MDR TB) alters lung architecture and involves lengthy treatment duration, high pill burden, drug adverse effects, travel restrictions, and stigma. Literature about pulmonary function and health-related quality of life (QoL) of patients treated for MDR TB is limited. This study sought to determine the prevalence of chronic obstructive pulmonary disease (COPD) and QoL of patients who were treated for pulmonary MDR TB. METHODS: Participants who completed 18 months of pulmonary MDR TB treatment and considered cured were eligible to be evaluated in a cross-sectional study. We performed post-bronchodilator spirometry to measure forced expiratory volume in 1 s (FEV(1)) and forced vital capacity (FVC). COPD was defined as FEV(1)/FVC < 0.7; health-related QoL was assessed using the Medical Outcomes Survey for HIV (MOS-HIV) and St. George’s Respiratory Questionnaire (SGRQ). Linear and logistic regression models were used to assess associations with COPD, health-related QoL, and other characteristics of the cohort. RESULTS: A total of 95 participants were enrolled. Median age of the cohort was 39 years (interquartile range (IQR), 29–45), and 55 (58%) were HIV-positive. COPD prevalence was 23% (22/95). Median SGRQ score was normal at 7.8 (IQR, 3.1–14.8). Median mental and physical health summary scores were significantly impaired, at 58.6 (IQR, 52.0–61.5) and 52.9 (IQR, 47.8–57.9), respectively, on a scale of 0 to 100 where 100 represents excellent physical or mental health. In this sample, 19% (18/95) of participants were in the lowest relative socioeconomic position (SEP) while 34% (32/95) were in the highest relative SEP. Belonging in the lowest SEP group was the strongest predictor of COPD. CONCLUSION: Individuals who have completed MDR TB treatment have a high prevalence of COPD and low mental and physical health summary scores. Our study highlights the need for pulmonary rehabilitation programs in patients with a low socioeconomic position (SEP) after MDR TB treatment.
format Online
Article
Text
id pubmed-7236316
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72363162020-05-29 Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study Nuwagira, Edwin Stadelman, Anna Baluku, Joseph Baruch Rhein, Joshua Byakika-Kibwika, Pauline Mayanja, Harriet Kunisaki, Ken M. Trop Med Health Research BACKGROUND: Pulmonary multi-drug-resistant tuberculosis (MDR TB) alters lung architecture and involves lengthy treatment duration, high pill burden, drug adverse effects, travel restrictions, and stigma. Literature about pulmonary function and health-related quality of life (QoL) of patients treated for MDR TB is limited. This study sought to determine the prevalence of chronic obstructive pulmonary disease (COPD) and QoL of patients who were treated for pulmonary MDR TB. METHODS: Participants who completed 18 months of pulmonary MDR TB treatment and considered cured were eligible to be evaluated in a cross-sectional study. We performed post-bronchodilator spirometry to measure forced expiratory volume in 1 s (FEV(1)) and forced vital capacity (FVC). COPD was defined as FEV(1)/FVC < 0.7; health-related QoL was assessed using the Medical Outcomes Survey for HIV (MOS-HIV) and St. George’s Respiratory Questionnaire (SGRQ). Linear and logistic regression models were used to assess associations with COPD, health-related QoL, and other characteristics of the cohort. RESULTS: A total of 95 participants were enrolled. Median age of the cohort was 39 years (interquartile range (IQR), 29–45), and 55 (58%) were HIV-positive. COPD prevalence was 23% (22/95). Median SGRQ score was normal at 7.8 (IQR, 3.1–14.8). Median mental and physical health summary scores were significantly impaired, at 58.6 (IQR, 52.0–61.5) and 52.9 (IQR, 47.8–57.9), respectively, on a scale of 0 to 100 where 100 represents excellent physical or mental health. In this sample, 19% (18/95) of participants were in the lowest relative socioeconomic position (SEP) while 34% (32/95) were in the highest relative SEP. Belonging in the lowest SEP group was the strongest predictor of COPD. CONCLUSION: Individuals who have completed MDR TB treatment have a high prevalence of COPD and low mental and physical health summary scores. Our study highlights the need for pulmonary rehabilitation programs in patients with a low socioeconomic position (SEP) after MDR TB treatment. BioMed Central 2020-05-19 /pmc/articles/PMC7236316/ /pubmed/32476983 http://dx.doi.org/10.1186/s41182-020-00221-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Research
Nuwagira, Edwin
Stadelman, Anna
Baluku, Joseph Baruch
Rhein, Joshua
Byakika-Kibwika, Pauline
Mayanja, Harriet
Kunisaki, Ken M.
Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study
title Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study
title_full Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study
title_fullStr Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study
title_full_unstemmed Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study
title_short Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study
title_sort obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in uganda: a cross-sectional study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236316/
https://www.ncbi.nlm.nih.gov/pubmed/32476983
http://dx.doi.org/10.1186/s41182-020-00221-y
work_keys_str_mv AT nuwagiraedwin obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy
AT stadelmananna obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy
AT balukujosephbaruch obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy
AT rheinjoshua obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy
AT byakikakibwikapauline obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy
AT mayanjaharriet obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy
AT kunisakikenm obstructivelungdiseaseandqualityoflifeaftercureofmultidrugresistanttuberculosisinugandaacrosssectionalstudy